论文部分内容阅读
目的 探讨格列吡嗪控释片对2型糖尿病患者血管内皮功能的影响。方法 76例2型糖尿病者,经2周洗脱期后,随机分为两组。一组4 0例应用格列吡嗪控释片;另一组36例应用格列本脲。根据达到目标血糖调整药物剂量,单药未能达标者加用阿卡波糖,治疗期12周。每位患者均采用高分辨率超声显像法,分别于治疗前后各进行一次右肱动脉血管内皮功能检测。结果 格列本脲组治疗前后肱动脉内径基础值、反应性充血及含服硝酸甘油后肱动脉内径变化,均无显著性差异[(3. 70±0 . 5 7)mm对(3 .72±0 . 5 9)mm ,(5 . 4 6±0 .82 ) %对(5 .70±0 .84 ) % ,(2 0 . 5±5 . 0 ) %对(2 0 . 1±5 . 1) % ,P >0 .0 5 ]。格列吡嗪控释片组治疗前后肱动脉内径基础值、含服硝酸甘油后肱动脉内径的变化,也无显著性差异[(3 .72±0 . 6 2 )mm对(3 .73±0 . 6 3)mm ,(19. 8±5. 5 ) %对(19. 9±5 . 8) % ,P >0 . 0 5 ];但反应性充血引起肱动脉内径变化,治疗前后具有非常显著性差异[(5. 6 7±0 .79) %对(9. 4 6±3 .81) % ,P <0 . 0 1]。结论 格列吡嗪控释片可能改善2型糖尿病者的血管内皮功能。
Objective To investigate the effect of glipizide controlled-release tablets on endothelial function in type 2 diabetic patients. Methods 76 patients with type 2 diabetes mellitus were randomly divided into two groups after 2 weeks of elution. A group of 40 cases of glipizide controlled-release tablets; the other 36 cases of glibenclamide. According to the target blood glucose to adjust the drug dose, monotherapy failed to meet the target plus acarbose, the treatment period of 12 weeks. Each patient with high-resolution ultrasound imaging, respectively, before and after treatment of right brachial artery endothelial function test. Results Before and after treatment with glibenclamide, there was no significant difference in the basic values of brachial artery internal diameter, reactive hyperemia and brachial artery diameter after oral administration of nitroglycerin [(3.70 ± 0.57) mm vs (3.72 ± 0.59) mm, (5.46 ± 0.82)% versus (5.70 ± 0.84)%, (20.5 ± 5.0%) vs (2.0 ± 5 . 1)%, P> 0 .0 5]. Glipizide controlled-release tablets before and after treatment of brachial artery diameter basic values, including nitroglycerin after brachial artery diameter changes, there was no significant difference [(3.72 ± 0.62) mm vs (3.73 ± (19.8 ± 5. 5)% vs (19.9 ± 5.8)%, P> 0.05). However, reactive hyperemia caused changes in the diameter of the brachial artery. Before and after treatment, Very significant difference [(5.67 ± 0.79)% vs (9.66 ± 3.81)%, P <0.01. Conclusion Glipizide controlled-release tablets may improve vascular endothelial function in type 2 diabetic patients.